This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.This is a multicenter, industry-sponsored study of a new experimental antidepressant, saredutant, that works by a novel mechanism unlike that of currently available antidepressants. During the first part of the study approximately 800 subjects will be enrolled at approximately 40 centers with a maximum expected 32 patients entered per treatment center. Responders will qualify to continue in the study, and will enter the second part of the study. Approximately 400 patients (200 patients/treatment group) will be randomized into the Maintenance Phase. The second part of this study uses a double-blind, placebo-controlled design to try to answer the question: Once symptoms of depression are improved after treatment with saredutant (SR48968C), does continued treatment with saredutant prevent relapse of depression?
Showing the most recent 10 out of 370 publications
